Articles On Neuren Pharmaceuticals (ASX:NEU)

The S&P/ASX 200 Index (ASX: XJO) ended its trading week on a low this Friday, banking a loss after a wild trading session. After spending some of the day comfortably in green territory, invest...

Pic via Getty ImagesRadiopharmaceuticals company Telix reports sustained revenue growth in Q4 FY24 ASX health stocks fall about 2.8% over past week Neuren’s partner Acadia submits marketing authorisation application in Europe for trofine...

It was a jubilant Thursday session for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, giving investors some much-needed relief. After a shaky week, the ASX 200 wasn't holding back...

Highlights ASX climbs 1.4% after robust jobs data. Commonwealth Bank (CBA) gains 2.7%. Neuren Pharmaceuticals (NEU) sees biggest single-session rise of 9%.   The Australian stock market rallied on Thursday, with the S&P/ASX 2...

The ASX200 closed down 0.22% at 8,213 points. The local bourse gave up early gains and slipped into the red in afternoon trade, and did not return to positive territory. The Discretionary sector was the best performer, up 0.2%, follow...

After a strong start to the morning's trade, things don't look so upbeat for the S&P/ASX 200 Index (ASX: XJO) this afternoon. At the time of writing, the ASX 200 has given up most of its early lead today, and is sitting pretty much flat...

The S&P/ASX 200 Index (ASX: XJO) is running out of steam and fighting hard to stay in positive territory. In afternoon trade, the benchmark index is up slightly to 8,230.9 points. Four ASX shares that are weighing on the market today...

Are you a fan of growth stocks? If you are, then it could be worth looking at the two ASX 200 growth shares listed below. That's because they have been named as buys by brokers and tipped to rise strongly from current levels. Here's what th...

It was another pleasant day for the S&P/ASX 200 Index (ASX: XJO) and Australian investors this Wednesday. After tentatively rising all week, investors stepped on the buying pedal this hump day...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Do you have $10,000 to invest into ASX 200 shares in January? If you do, then it could be worth considering the two shares in this article. Let's see why they could be great options for investors this month: Neuren Pharmaceuticals Ltd (AS...

Highlights - The ASX 200 index closed 0.92% lower during the final session of 2024.  - Nine out of eleven sectors recorded declines, led by gold and consumer-focused stocks.  - Energy stocks were the top performers as crude prices sup...

Morgans sees opportunities among several ASX healthcare stocks in 2025 Broker looking at stocks with near-term catalysts or sold down with good entry opportunities Morgans’ Christmas stocking has mix of up-and-comers alongside mature names...

Looking for growth stocks to buy in 2025? If you are, then it could be worth looking at the three ASX 200 growth shares listed below. They have been named as buys by brokers and tipped to rise strongly from current levels. Here's what they...

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

If you are fortunate enough to have $5,000 spare to invest into ASX 200 shares, then read on. That's because listed below are three shares that analysts are tipping as top buys for the year ahead. Here's what you need to know about them: D...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Index (ASX: XJO) suffered another fall this Wednesday, helping to cement what has been a fairly rough week for the Australian market. After a brief foray into positive ter...

Syntara aims for FDA ‘breakthrough’ therapy status for its myelofibrosis drug candidate FAK! More promising results from Amplia’s pancreatic cancer trial Oh, you shouldn’t have! Broker Morgans’ Christmas biotech hamper   Armed with encour...

Last Friday, the Fat Tail Investment Research crew gathered in our South Melbourne office for our annual Christmas party. We enjoyed light conversations, karaoke singing and thank-you speeches over sushi, fried chicken, snacks, beers and o...

It was another fantastic day for the S&P/ASX 200 Index (ASX: XJO) this Tuesday, with the index hitting its latest new all-time high. The ASX 200 added 0.56% by the close of today's session, le...

The intrigue of ASX growth shares enthrals many investors. Often, stocks in this category catch headlines and see their shares bid up to high prices. Qualifying these companies for 'growth' is the growth in their historical and future...

Highlights  ASX200 falls 0.57% after touching a record high near 8,400 points.    Health Care sector posts modest gains despite broad losses.   Small-cap stocks show strong individual performances. The Australian Securities Exchan...

ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7%  Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate...

The best ASX shares in terms of share price gains since the US election make for interesting reading. Based on data from S & P Global Market Intelligence, here are the top 10 ASX 200 shares. Best-performing ASX 200 shares since...

The S&P/ASX 200 Index (ASX: XJO) managed to snap the three-day losing streak it had been on this week to push higher today. After falling all week, ASX investors appeared to decide enou...

Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, whic...

The S&P/ASX 200 Index (ASX: XJO) endured another rough day of trading this Tuesday, making the trading week so far a bit of a downer. After getting a walkback from investors yesterday, th...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. At the time of writing, the benchmark index is down 0.5% to 8,223.4 points. Four ASX shares that are not letting that hold them back today ar...

The market may be nearing a record high, but that doesn't mean there aren't big potential gains to be made. For example, the ASX 200 share in this article, which is swimming in cash, has been tipped rise very strongly from current levels. W...

The S&P/ASX 200 Index (ASX: XJO) enjoyed an enthusiastic end to the trading week this Friday, giving investors a tangible boost as we head into the weekend. After spending all day in positi...

Highlights ASX gains on Fed rate cuts and China's potential stimulus. Life360 and Commonwealth Bank hit new highs. Mining and tech stocks lead the rally, with notable rises in iron ore and gold. Australian shares rallied on Friday...

Highlights  S&P/ASX 200 rises on global rate cuts and China stimulus hopes.   Tech and banking stocks soar; energy sector lags.    Block Inc drops despite strong profits. The Australian share market showed positive momentum i...

ASX rallies broadly as tech stocks lead Commonwealth Bank hits record, Neuren jumps Asian markets rise, China stimulus eyed   The ASX was riding the coattails of a strong Wall Street session, with tech stocks leading the charge.  At the c...

The S&P/ASX 200 Index (ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed below. Here's why they are charging...

It was a wild session for the S&P/ASX 200 Index (ASX: XJO) this Thursday as investors continued to digest the impact of this week's American elections. After several stints in both positive...

ASX slipped after early gains, then finished strongly  Energy sector helped offset losses; Quickstep, Sigma Healthcare turned heads Wall Street rallied to record highs after Trump’s win   The ASX swung from gains, to losses at lunchtime,...

Highlights  ASX gains slightly, led by energy and mining sectors on China stimulus hopes. Banking sector mixed as rate-sensitive stocks face pressure. Sigma Healthcare and Neuren post significant gains following positive development...

The S&P/ASX 200 Index (ASX: XJO) has failed to follow Wall Street's stunning lead and has dropped into the red. In afternoon trade, the benchmark index is down 0.2% to 8,182.9 points. Four ASX shares that are not letting that hold them...

Highlights  ASX edges lower due to declines in property sector despite gains in other sectors. National Australia Bank posts mixed results, while big miners show slight advances. Sigma Healthcare soars on regulatory approval for a key...

Highlights Australian shares dip as miners and banks retreat post-U.S. election. Notable drops in major banks and gold stocks impact ASX performance.  Positive gains for Sigma Healthcare, Steadfast, and Neuren Pharmaceuticals. Au...

Having pocketed a US$50 million share of an FDA priority review voucher, Neuren reports bumper results. ACCC says ‘no probs’ to Sigma-Chemist Warehouse union  The Trump Ascendency Mark Two is a double-edged sword for the healthcare sector...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin National Australia Bank ((NAB)) has released an FY24 result largely in line with ana...

The ASX200 has been up 0.83% at 8199 points. Counting in the US election continues and markets are eagerly watching the results trickle in and are reacting accordingly. All sectors have gained ground and the IT sector has been the bes...

Neuren Pharmaceuticals (ASX: NEU), a Melbourne-based biotech that is developing therapies for neurodevelopmental disorders in early childhood, has scored a cash windfall from the US$150 million ($229 million) sale of a Rare Paediatric Disea...

ASX healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has surged in early trade on Wednesday after a company update. Shares in the biopharma company currently fetch $12.95 apiece, nearly 6% higher on the day after it announced it w...

Neuren Pharmaceuticals (ASX:NEU) is set to receive a substantial payout following the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its US-based partner, Acadia Pharmaceuticals (NASDAQ: ACAD), for $US150m. Under the agre...

Are you on the hunt for big returns to supercharge your portfolio? If you are, then it could pay to listen to what analysts are saying about the ASX 200 growth stocks listed below. Here's why analysts are feeling bullish about these stocks...

Looking for big returns to supercharge your investment portfolio? If you are, it could be worth checking out the two ASX 200 growth shares listed below that have been tipped to rise strongly from current levels. Here's what analysts are say...

What’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Formerly known as Antisense Therapeutics, the rare disease specialist changed its name to Percheron in January. Percheron means ‘draught horse...